Trans-fatty acids killing 5.4 lakh a year: Govt

NEW DELHI : High intake of trans-fatty acids increases the risk of coronary heart disease, Union health minister Mansukh Mandaviya told Lok Sabha on Friday.

In a written reply to a Parliament question, Mandaviya said industrially produced trans-fat is commonly found in packaged foods, baked goods, cooking oil and spreads. “Approximately 5,40,000 deaths each year are estimated to be attributed to the intake of industrially produced trans-fatty acids,” he said. The health minister said that high trans-fat intake may increase the risk of death from any cause by 34%, and coronary heart disease deaths by 28%.
“This is likely due to the effect on lipid levels: trans-fat increases LDL (low-density lipoprotein) or bad cholesterol levels while lowering HDL (high-density lipoprotein) or good cholesterol levels. According to the World Health Organisation, 4.6% of coronary heart disease deaths in India may be related to trans-fatty acid intake ( 0.5% of energy intake),” Mandaviya said.

Food Safety Standard Authority of India (FSSAI) has implemented best-practice policy as specified by WHO to gradually reduce the trans-fats consumption in India.

In this regard, the health minister explained, FSSAI has notified the Food Safety and Standards (Prohibition and Restrictions on Sales) Second Amendment Regulations, 2021, on February 2, 2020, and Food Safety and Standards (Food Products Standards and Food Additives) Tenth Amendment Regulations, 2020, on December 29, 2020, to reduce the maximum limit of industrial trans-fatty acids to not more than 2% by weight in edible oils, fats and food products in which edible oils and fats are used as an ingredient. “These amendments came into effect from January 1, 2022. The changes introduced are in line with recommendations of the World Health Organisation,” he added.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March